Skip to main content
NCBI home page
Clinical Molecular Pathology logoLink to Clinical Molecular Pathology
. 1995 Dec;48(6):M333–M341. doi: 10.1136/mp.48.6.m333

IGF-II dependent autocrine growth in cell lines derived from renal tumours of childhood

W Zumkeller 1,2, A Mahmood 1,2, R Dellow 1,2, P N Schofield 1,2
PMCID: PMC408001  PMID: 16696034

Abstract

Aims—To determine the role of insulin-like growth factors (IGF) in the proliferation of tumour cells, by studying the mitogenic response to IGFs of three cell lines of differing phenotype established from both malignant rhabdoid and Wilms tumour, representing a range of cell types (GOS 4, G401, and T3/73).

Methods—Production of IGF-II and IGF-I was measured by radioimmunoassay, and the presence of IGF binding protein complexes was observed by gel exclusion chromatography. Following growth analyses in serum-free media to ascertain the dependence of the cell lines on exogenous IGFs, the generation of autocrine growth was measured by a density dependence assay of proliferation in culture. Receptors were measured by radioligand cross linking and autocrine growth through these receptors assayed by the use of blocking antibodies.

Results—While GOS 4 and G401 were able to proliferate in serum-free medium over a period of 5 d, T3/73 showed an absolute dependence on IGFs added daily at 1-10 ng/ml. Plating at clonal density showed that cell growth was directly density dependent in serum-free medium. The serum independent proliferation of G401 and GOS 4 was blocked by the addition of an antibody to the type 1 IGF receptor (α-IR3) suggesting that the effects of autocrine factors are mediated through type 1 IGF receptors. S1 nuclease protection analysis indicated that all three cell lines produced significant amounts of mRNA derived mainly from the P3 IGF-II promoter, but transcripts for IGF-I were undetectable. Radioimmunoassay of IGFs from conditioned media showed that all the lines made assayable IGF-II (8·6, 8·4, and 6·1 ng/ml/24 h/106 cells for GOS 4, G401, and T3/73 respectively). The presence of species consistent with both type 1 and type II IGF receptors was demonstrated using radioligand binding to cell membranes followed by cross linking.

Conclusions—Autocrine IGF-II may contribute to the serum independence of GOS 4 and G401 cells, whereas T3/73 may depend on exogenous IGF-II for proliferation.

Keywords: Wilms tumour

Keywords: malignant rhabdoid tumour

Keywords: insulin-like growth factor II

Full text

PDF
M333

Images in this article

M337Image
on p.M337
M338Image
on p.M338

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baccarini P., Fiorentino M., D'Errico A., Mancini A. M., Grigioni W. F. Detection of anti-sense transcripts of the insulin-like growth factor-2 gene in Wilms' tumor. Am J Pathol. 1993 Dec;143(6):1535–1542. [PMC free article] [PubMed] [Google Scholar]
  2. Beckwith J. B., Kiviat N. B., Bonadio J. F. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol. 1990;10(1-2):1–36. doi: 10.3109/15513819009067094. [DOI] [PubMed] [Google Scholar]
  3. Berstine E. G., Hooper M. L., Grandchamp S., Ephrussi B. Alkaline phosphatase activity in mouse teratoma. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3899–3903. doi: 10.1073/pnas.70.12.3899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Biddle C., Li C. H., Schofield P. N., Tate V. E., Hopkins B., Engstrom W., Huskisson N. S., Graham C. F. Insulin-like growth factors and the multiplication of Tera-2, a human teratoma-derived cell line. J Cell Sci. 1988 Jul;90(Pt 3):475–484. doi: 10.1242/jcs.90.3.475. [DOI] [PubMed] [Google Scholar]
  5. Chirgwin J. M., Przybyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979 Nov 27;18(24):5294–5299. doi: 10.1021/bi00591a005. [DOI] [PubMed] [Google Scholar]
  6. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994 Jun 2;369(6479):414–418. doi: 10.1038/369414a0. [DOI] [PubMed] [Google Scholar]
  7. Dowdy S. F., Weissman B. E., Stanbridge E. J. Correlation of the inability to sustain growth in defined serum-free medium with the suppression of tumorigenicity in Wilms' nephroblastoma. J Cell Physiol. 1991 May;147(2):248–255. doi: 10.1002/jcp.1041470209. [DOI] [PubMed] [Google Scholar]
  8. Drummond I. A., Madden S. L., Rohwer-Nutter P., Bell G. I., Sukhatme V. P., Rauscher F. J., 3rd Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science. 1992 Jul 31;257(5070):674–678. doi: 10.1126/science.1323141. [DOI] [PubMed] [Google Scholar]
  9. El-Badry O. M., Romanus J. A., Helman L. J., Cooper M. J., Rechler M. M., Israel M. A. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989 Sep;84(3):829–839. doi: 10.1172/JCI114243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gansler T., Allen K. D., Burant C. F., Inabnett T., Scott A., Buse M. G., Sens D. A., Garvin A. J. Detection of type 1 insulinlike growth factor (IGF) receptors in Wilms' tumors. Am J Pathol. 1988 Mar;130(3):431–435. [PMC free article] [PubMed] [Google Scholar]
  11. Gansler T., Furlanetto R., Gramling T. S., Robinson K. A., Blocker N., Buse M. G., Sens D. A., Garvin A. J. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol. 1989 Dec;135(6):961–966. [PMC free article] [PubMed] [Google Scholar]
  12. Garvin A. J., Re G. G., Tarnowski B. I., Hazen-Martin D. J., Sens D. A. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol. 1993 Feb;142(2):375–380. [PMC free article] [PubMed] [Google Scholar]
  13. Garvin A. J., Sullivan J. L., Bennett D. D., Stanley W. S., Inabnett T., Sens D. A. The in vitro growth, heterotransplantation, and immunohistochemical characterization of the blastemal component of Wilms' tumor. Am J Pathol. 1987 Nov;129(2):353–363. [PMC free article] [PubMed] [Google Scholar]
  14. Granerus M., Bierke P., Zumkeller W., Smith J., Engström W., Schofield P. N. Insulin-like growth factor II prevents apoptosis in a human teratoma derived cell line. Clin Mol Pathol. 1995 Jun;48(3):M153–M157. doi: 10.1136/mp.48.3.m153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Haselbacher G. K., Irminger J. C., Zapf J., Ziegler W. H., Humbel R. E. Insulin-like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1104–1106. doi: 10.1073/pnas.84.4.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hill D. J. Relative abundance and molecular size of immunoreactive insulin-like growth factors I and II in human fetal tissues. Early Hum Dev. 1990 Jan;21(1):49–58. doi: 10.1016/0378-3782(90)90110-5. [DOI] [PubMed] [Google Scholar]
  17. Irminger J. C., Schoenle E. J., Briner J., Humbel R. E. Structural alteration of the insulin-like growth factor II-gene in Wilms tumour. Eur J Pediatr. 1989 Jun;148(7):620–623. doi: 10.1007/BF00441514. [DOI] [PubMed] [Google Scholar]
  18. Kull F. C., Jr, Jacobs S., Su Y. F., Svoboda M. E., Van Wyk J. J., Cuatrecasas P. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem. 1983 May 25;258(10):6561–6566. [PubMed] [Google Scholar]
  19. Kumar S., Harrison C. J., Heighway J., Marsden H. B., West D. C., Jones P. M. A cell line from Wilms' tumour with deletion in short arm of chromosome II. Int J Cancer. 1987 Oct 15;40(4):499–504. doi: 10.1002/ijc.2910400412. [DOI] [PubMed] [Google Scholar]
  20. Little M. H., Ablett G., Smith P. J. Enhanced expression of insulin-like growth factor II is not a necessary event in Wilms' tumour progression. Carcinogenesis. 1987 Jun;8(6):865–868. doi: 10.1093/carcin/8.6.865. [DOI] [PubMed] [Google Scholar]
  21. Macaulay V. M. Insulin-like growth factors and cancer. Br J Cancer. 1992 Mar;65(3):311–320. doi: 10.1038/bjc.1992.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Maitland N. J., Brown K. W., Poirier V., Shaw A. P., Williams J. Molecular and cellular biology of Wilms' tumour. Anticancer Res. 1989 Sep-Oct;9(5):1417–1426. [PubMed] [Google Scholar]
  23. Manni A., Badger B., Wei L., Zaenglein A., Grove R., Khin S., Heitjan D., Shimasaki S., Ling N. Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res. 1994 Jun 1;54(11):2934–2942. [PubMed] [Google Scholar]
  24. Minniti C. P., Maggi M., Helman L. J. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 1992 Apr 1;52(7):1830–1835. [PubMed] [Google Scholar]
  25. Morrell D. J., Dadi H., More J., Taylor A. M., Dabestani A., Buchanan C. R., Holder A. T., Preece M. A. A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. J Mol Endocrinol. 1989 May;2(3):201–206. doi: 10.1677/jme.0.0020201. [DOI] [PubMed] [Google Scholar]
  26. Moulton T., Crenshaw T., Hao Y., Moosikasuwan J., Lin N., Dembitzer F., Hensle T., Weiss L., McMorrow L., Loew T. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet. 1994 Jul;7(3):440–447. doi: 10.1038/ng0794-440. [DOI] [PubMed] [Google Scholar]
  27. Newell S., Ward A., Graham C. Discriminating translation of insulin-like growth factor-II (IGF-II) during mouse embryogenesis. Mol Reprod Dev. 1994 Nov;39(3):249–258. doi: 10.1002/mrd.1080390302. [DOI] [PubMed] [Google Scholar]
  28. Ogawa O., Eccles M. R., Szeto J., McNoe L. A., Yun K., Maw M. A., Smith P. J., Reeve A. E. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature. 1993 Apr 22;362(6422):749–751. doi: 10.1038/362749a0. [DOI] [PubMed] [Google Scholar]
  29. Ohlsson R., Nyström A., Pfeifer-Ohlsson S., Töhönen V., Hedborg F., Schofield P., Flam F., Ekström T. J. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat Genet. 1993 May;4(1):94–97. doi: 10.1038/ng0593-94. [DOI] [PubMed] [Google Scholar]
  30. Osborne C. K., Coronado E. B., Kitten L. J., Arteaga C. I., Fuqua S. A., Ramasharma K., Marshall M., Li C. H. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov;3(11):1701–1709. doi: 10.1210/mend-3-11-1701. [DOI] [PubMed] [Google Scholar]
  31. Paik S., Rosen N., Jung W., You J. M., Lippman M. E., Perdue J. F., Yee D. Expression of insulin-like growth factor-II mRNA in fetal kidney and Wilms' tumor. An in situ hybridization study. Lab Invest. 1989 Nov;61(5):522–526. [PubMed] [Google Scholar]
  32. Pedone P. V., Tirabosco R., Cavazzana A. O., Ungaro P., Basso G., Luksch R., Carli M., Bruni C. B., Frunzio R., Riccio A. Mono- and bi-allelic expression of insulin-like growth factor II gene in human muscle tumors. Hum Mol Genet. 1994 Jul;3(7):1117–1121. doi: 10.1093/hmg/3.7.1117. [DOI] [PubMed] [Google Scholar]
  33. Re G. G., Hazen-Martin D. J., Sens D. A., Garvin A. J. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development. Semin Diagn Pathol. 1994 May;11(2):126–135. [PubMed] [Google Scholar]
  34. Reeve A. E., Eccles M. R., Wilkins R. J., Bell G. I., Millow L. J. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature. 1985 Sep 19;317(6034):258–260. doi: 10.1038/317258a0. [DOI] [PubMed] [Google Scholar]
  35. Ren-Qiu Q., Ruelicke T., Hassam S., Haselbacher G. K., Schoenle E. J. Systemic effects of insulin-like growth factor-II produced and released from Wilms tumour tissue. Eur J Pediatr. 1993 Feb;152(2):102–106. doi: 10.1007/BF02072483. [DOI] [PubMed] [Google Scholar]
  36. Rogers S. A., Ryan G., Hammerman M. R. Insulin-like growth factors I and II are produced in the metanephros and are required for growth and development in vitro. J Cell Biol. 1991 Jun;113(6):1447–1453. doi: 10.1083/jcb.113.6.1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sait S. N., Nowak N. J., Singh-Kahlon P., Weksberg R., Squire J., Shows T. B., Higgins M. J. Localization of Beckwith-Wiedemann and rhabdoid tumor chromosome rearrangements to a defined interval in chromosome band 11p15.5. Genes Chromosomes Cancer. 1994 Oct;11(2):97–105. doi: 10.1002/gcc.2870110206. [DOI] [PubMed] [Google Scholar]
  38. Schmidt D., Harms D., Zieger G. Malignant rhabdoid tumor of the kidney. Histopathology, ultrastructure and comments on differential diagnosis. Virchows Arch A Pathol Anat Histopathol. 1982;398(1):101–108. doi: 10.1007/BF00585617. [DOI] [PubMed] [Google Scholar]
  39. Schofield P. N., Engstrom W., Lee A. J., Biddle C., Graham C. F. Expression of c-myc during differentiation of the human teratocarcinoma cell line Tera-2. J Cell Sci. 1987 Aug;88(Pt 1):57–64. doi: 10.1242/jcs.88.1.57. [DOI] [PubMed] [Google Scholar]
  40. Schofield P. N., Granerus M., Tally M., Engström W. The biological effects of a high molecular weight form of IGF II in a pluripotential human teratocarcinoma cell line. Anticancer Res. 1994 Mar-Apr;14(2A):533–538. [PubMed] [Google Scholar]
  41. Schofield P. N., Lee A., Hill D. J., Cheetham J. E., James D., Stewart C. Tumour suppression associated with expression of human insulin-like growth factor II. Br J Cancer. 1991 May;63(5):687–692. doi: 10.1038/bjc.1991.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Schofield P. N., Tate V. E. Regulation of human IGF-II transcription in fetal and adult tissues. Development. 1987 Dec;101(4):793–803. doi: 10.1242/dev.101.4.793. [DOI] [PubMed] [Google Scholar]
  43. Scott J., Cowell J., Robertson M. E., Priestley L. M., Wadey R., Hopkins B., Pritchard J., Bell G. I., Rall L. B., Graham C. F. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature. 1985 Sep 19;317(6034):260–262. doi: 10.1038/317260a0. [DOI] [PubMed] [Google Scholar]
  44. Sell C., Dumenil G., Deveaud C., Miura M., Coppola D., DeAngelis T., Rubin R., Efstratiadis A., Baserga R. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994 Jun;14(6):3604–3612. doi: 10.1128/mcb.14.6.3604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Smith J., Fowkes G., Schofield P. N. Programmed cell death in dystrophic (mdx) muscle is inhibited by IGF-II. Cell Death Differ. 1995 Oct;2(4):243–251. [PubMed] [Google Scholar]
  46. Steele-Perkins G., Turner J., Edman J. C., Hari J., Pierce S. B., Stover C., Rutter W. J., Roth R. A. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem. 1988 Aug 15;263(23):11486–11492. [PubMed] [Google Scholar]
  47. Steenman M. J., Rainier S., Dobry C. J., Grundy P., Horon I. L., Feinberg A. P. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet. 1994 Jul;7(3):433–439. doi: 10.1038/ng0794-433. [DOI] [PubMed] [Google Scholar]
  48. Sussenbach J. S., Steenbergh P. H., Holthuizen P. Structure and expression of the human insulin-like growth factor genes. Growth Regul. 1992 Mar;2(1):1–9. [PubMed] [Google Scholar]
  49. Vincent T. S., Garvin A. J., Gramling T. S., Hazen-Martin D. J., Re G. G., Sens D. A. Expression of insulin-like growth factor binding protein 2 (IGFBP-2) in Wilms' tumors. Pediatr Pathol. 1994 Jul-Aug;14(4):723–730. doi: 10.3109/15513819409023344. [DOI] [PubMed] [Google Scholar]
  50. Ward A., Bates P., Fisher R., Richardson L., Graham C. F. Disproportionate growth in mice with Igf-2 transgenes. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10365–10369. doi: 10.1073/pnas.91.22.10365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Weissman B. E., Saxon P. J., Pasquale S. R., Jones G. R., Geiser A. G., Stanbridge E. J. Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression. Science. 1987 Apr 10;236(4798):175–180. doi: 10.1126/science.3031816. [DOI] [PubMed] [Google Scholar]
  52. Weksberg R., Shen D. R., Fei Y. L., Song Q. L., Squire J. Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome. Nat Genet. 1993 Oct;5(2):143–150. doi: 10.1038/ng1093-143. [DOI] [PubMed] [Google Scholar]
  53. Werner H., Re G. G., Drummond I. A., Sukhatme V. P., Rauscher F. J., 3rd, Sens D. A., Garvin A. J., LeRoith D., Roberts C. T., Jr Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5828–5832. doi: 10.1073/pnas.90.12.5828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yun K., Molenaar A. J., Fiedler A. M., Mark A. J., Eccles M. R., Becroft D. M., Reeve A. E. Insulin-like growth factor II messenger ribonucleic acid expression in Wilms tumor, nephrogenic rest, and kidney. Lab Invest. 1993 Nov;69(5):603–615. [PubMed] [Google Scholar]
  55. Zumkeller W., Schofield P. N. The role of insulin-like growth factors and IGF-binding proteins in the physiological and pathological processes of the kidney. Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(4):207–220. doi: 10.1007/BF02899684. [DOI] [PubMed] [Google Scholar]
  56. Zumkeller W., Schwander J., Mitchell C. D., Morrell D. J., Schofield P. N., Preece M. A. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP-2) in the plasma of children with Wilms' tumour. Eur J Cancer. 1993;29A(14):1973–1977. doi: 10.1016/0959-8049(93)90455-o. [DOI] [PubMed] [Google Scholar]
  57. de Pagter-Holthuizen P., Jansen M., van Schaik F. M., van der Kammen R., Oosterwijk C., Van den Brande J. L., Sussenbach J. S. The human insulin-like growth factor II gene contains two development-specific promoters. FEBS Lett. 1987 Apr 20;214(2):259–264. doi: 10.1016/0014-5793(87)80066-2. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES